Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial

BACKGROUND AND PURPOSE:Clopidogrel is an antiplatelet drug that is metabolized to its active form by the CYP2C19 enzyme. The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) found a significant interaction between loss-of-function allele status for the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Stroke (1970) 2020-07, Vol.51 (7), p.2058-2065
Hauptverfasser:	Meschia, James F., Walton, Ronald L., Farrugia, Luca P., Ross, Owen A., Elm, Jordan J., Farrant, Mary, Meurer, William J., Lindblad, Anne S., Barsan, William, Ching, Marilou, Gentile, Nina, Ross, Michael, Nahab, Fadi, Easton, J. Donald, Kim, Anthony S., Zurita, Karla G., Cucchiara, Brett, Johnston, S. Claiborne
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!